What is the 13F Pro Quality Score for BDX?

13F Pro ranks BECTON DICKINSON & CO (BDX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BDX's current score at https://13fpro.ai/company/BDX (free sign-up required for the full ranking).

Where does 13F Pro source BDX data?

All BECTON DICKINSON & CO fundamentals and ownership data come directly from SEC EDGAR. BECTON DICKINSON & CO files with the SEC under CIK 10795. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BDX in?

BECTON DICKINSON & CO (BDX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BDX research updated on 13F Pro?

BDX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BECTON DICKINSON & CO(BDX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSElarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 10795 BDX stock profile & AI dashboard →

13F Pro Quality Score

59.0/100

Rank #957 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

49.6/100

Profitability

35.7/100

Balance Sheet

51.2/100

Earnings Quality

92.2/100

Free Cash Flow

59.5/100

Institutional Flow

63.6/100

Revenue Scale

93.3/100

Dilution Risk

52.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BDX Scores 59/100

exact factor attribution · 2026-09-11

BDX's composite is driven by scale and earnings quality, held back by profitability and earnings growth. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Scale

+6.5 pts

93th pct

Earnings quality

+4.2 pts

92th pct

Free cash flow

+1.4 pts

60th pct

Institutional flow

+0.7 pts

64th pct

Capital efficiency

+0.1 pts

51th pct

Shareholder dilution

+0.1 pts

53th pct

Revenue growth

-0.1 pts

50th pct

Earnings growth

-1.8 pts

14th pct

Profitability

-2.1 pts

36th pct

Latest change (2026-08-06): 51 → 54 · ↑ Revenue growth 36→44; ↑ Free cash flow 66→74

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BDX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BECTON DICKINSON & CO (BDX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BDX at 59.0/100 on a 32-signal composite quality model, placing it at rank #957 of 2,961 stocks — the top half of the AI-ranked universe. BDX scores in the top quartile across revenue scale (93.3), earnings quality (92.2). Areas of concern include profitability (35.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), BECTON DICKINSON & CO reports quarterly revenue of $5.0B, net income of $377.0M, an operating margin of 13.3%. Top institutional holders of BDX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, MASSACHUSETTS FINANCIAL SERVICES, based on the most recent SEC filings. BDX trades on the NYSE exchange and files with the SEC under CIK 10795. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BECTON DICKINSON & CO directly from SEC EDGAR. BECTON DICKINSON & CO's 13F Pro composite quality score has ranged between 52 and 69 since 2021, currently 59.0 — a declining long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about BECTON DICKINSON & CO

Quirks, history, and lore behind BDX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on the NYSE · headquartered in New Jersey.
2
The Numbers
Annual revenue of roughly $20 billion, with operations spanning 190+ countries — it's one of the largest medical technology companies on the planet.
3
The History
Founded in 1897, it has been making needles and syringes longer than most companies have existed, and it helped standardize those products for modern medicine.
4
The Secret
It's quietly one of the world's biggest suppliers of prefillable drug delivery systems and diagnostic instruments — the behind-the-scenes backbone of hospitals everywhere.
5
The Lore
Its 2017 acquisition of C.R. Bard for roughly $24 billion was one of the largest deals in medical device history, bolting on a full vascular and surgery portfolio overnight.
6
The Giveaway
Two last names, a century of syringes, and a ticker that sounds like a stock market sound effect — this is the company behind billions of vaccine injections every single year.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$5.0B

Net Income

Q2 2026

$377.0M

Free Cash Flow

Q2 2026

$633.0M

Operating Margin

Q2 2026

13.3%

ROIC

Q2 2026

6.4%

D/E Ratio

Q2 2026

0.69

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+8.2% YoY

$21.84BFY 2025

FY22 $18.87BFY23 $19.37BFY24 $20.18BFY25 $21.84B

Net Income

-1.6% YoY

$1.68BFY 2025

FY22 $1.78BFY23 $1.48BFY24 $1.71BFY25 $1.68B

Operating Income

+7.6% YoY

$2.58BFY 2025

FY22 $2.28BFY23 $2.11BFY24 $2.40BFY25 $2.58B

EPS (Diluted)

-0.7% YoY

$5.82FY 2025

FY22 $5.88FY23 $4.94FY24 $5.86FY25 $5.82

Total Assets

-3.4% YoY

$55.33BFY 2025

FY22 $52.93BFY23 $52.78BFY24 $57.29BFY25 $55.33B

Total Debt

-4.6% YoY

$19.18BFY 2025

FY22 $16.07BFY23 $15.88BFY24 $20.11BFY25 $19.18B

Op. Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$21.84B +8.2%	$20.18B +4.2%	$19.37B +2.7%	$18.87B -1.4%	$19.13B +19.0%	$16.07B
Net Income	$1.68B -1.6%	$1.71B +14.9%	$1.48B -16.6%	$1.78B -15.0%	$2.09B +139.4%	$874.0M
Operating Income	$2.58B +7.6%	$2.40B +13.5%	$2.11B -7.5%	$2.28B +1.4%	$2.25B +146.7%	$912.0M
EPS (Diluted)	$5.82 -0.7%	$5.86 +18.6%	$4.94 -16.0%	$5.88 -14.2%	$6.85 +152.8%	$2.71
Total Assets	$55.33B -3.4%	$57.29B +8.5%	$52.78B -0.3%	$52.93B -1.7%	$53.87B -0.3%	$54.01B
Total Debt	$19.18B -4.6%	$20.11B +26.6%	$15.88B -1.2%	$16.07B -8.8%	$17.61B -1.8%	$17.93B
Operating Cash Flow	—	—	—	—	$4.65B +31.3%	$3.54B
Free Cash Flow	—	—	—	—	$3.45B +24.7%	$2.77B

Get alerted when BDX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BECTON DICKINSON & CO including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BDX

BlackRock, Inc.
$3.7B24,592,166 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.7B17,987,834 sh
MASSACHUSETTS FINANCIAL SERVICES CO /MA/
$2.5B8,650,967 sh
STATE STREET CORP
$2.3B15,000,064 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.3B14,974,136 sh
First Eagle Investment Management, LLC
$2.1B13,815,335 sh
Invesco Ltd.
$1.3B8,898,488 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.2B8,141,586 sh
FRANKLIN RESOURCES INC
$1.1B7,011,592 sh
WELLINGTON MANAGEMENT GROUP LLP
$962.2M6,357,986 sh

Fund	Value	Shares
BlackRock, Inc.	$3.7B	24,592,166
VANGUARD CAPITAL MANAGEMENT LLC	$2.7B	17,987,834
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	$2.5B	8,650,967
STATE STREET CORP	$2.3B	15,000,064
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.3B	14,974,136
First Eagle Investment Management, LLC	$2.1B	13,815,335
Invesco Ltd.	$1.3B	8,898,488
GEODE CAPITAL MANAGEMENT, LLC	$1.2B	8,141,586
FRANKLIN RESOURCES INC	$1.1B	7,011,592
WELLINGTON MANAGEMENT GROUP LLP	$962.2M	6,357,986

Companies Similar to BDX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PFE

PFIZER INC

AI score

Very similar · 32 shared holders

BRANDES INVESTMENT PARTNERS, LP STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

MRK

Merck & Co., Inc.

AI score

Very similar · 34 shared holders

HARRIS ASSOCIATES L P Beutel, Goodman & Co Ltd.BRANDES INVESTMENT PARTNERS, LP

CVS

CVS HEALTH Corp

AI score

Very similar · 31 shared holders

Clearbridge Investments, LLC BRANDES INVESTMENT PARTNERS, LP NORDEA INVESTMENT MANAGEMENT AB

ZBH

ZIMMER BIOMET HOLDINGS, INC.

AI score

Very similar · 30 shared holders

HARRIS ASSOCIATES L P Boston Trust Walden Corp Meridiem Capital Partners LP

ELV

Elevance Health, Inc.

AI score

Very similar · 28 shared holders

First Eagle Investment Management, LLC HARRIS ASSOCIATES L P Beutel, Goodman & Co Ltd.

ABT

ABBOTT LABORATORIES

AI score

Very similar · 37 shared holders

M&G Plc STATE FARM MUTUAL AUTOMOBILE INSURANCE CO National Pension Service

MDT

Medtronic plc

AI score

Very similar · 36 shared holders

First Eagle Investment Management, LLC Beutel, Goodman & Co Ltd.FORT WASHINGTON INVESTMENT ADVISORS INC /OH/

IQV

IQVIA HOLDINGS INC.

AI score

Very similar · 24 shared holders

HARRIS ASSOCIATES L P Longview Partners (Guernsey) LTD GREENHAVEN ASSOCIATES INC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BDX on your watchlist

Track score changes the day BECTON DICKINSON & CO files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BDX a good stock to buy?

13F Pro's AI-powered analysis of BECTON DICKINSON & CO (BDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BDX are available on the BDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BDX is classified as a large company.

Which hedge funds own BDX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BECTON DICKINSON & CO's investment landscape.